“Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s317. doi:10.25251/skin.8.supp.317.